Immunology of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. An update. 1987

M Seligmann, and A J Pinching, and F S Rosen, and J L Fahey, and R M Khaitov, and D Klatzmann, and S Koenig, and N Luo, and J Ngu, and G Riethmüller

Recent advances in the understanding of the pathogenesis of infection with human immunodeficiency virus (HIV) stems from the demonstration that the membrane glycoprotein, CD4, is the cellular receptor for HIV. This glycoprotein is found mainly on the surface of a major subpopulation of T lymphocytes and also on macrophages, natural killer cells, some B lymphocytes, and neuronal cells. Cells infected with HIV may be destroyed or have their normal function impaired. Host immune responses to HIV are poor and are not sustained. Neutralizing antibody often is not produced, or HIV may escape from normal immunosuppressive mechanisms through the process of rapid antigenic variation. Factors and markers that may be important in the outcome or that may predict progression of HIV infection are genetic (Gc type), environmental (nutritional status or intercurrent sexually transmitted diseases sustained by the host), and immunologic (rate of decline in number and impairment of function of CD4 lymphocytes and of decline in antibody titers to HIV core protein, p24). A recombinant vaccine will probably be developed for testing in future clinical trials.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D011991 Receptors, Virus Specific molecular components of the cell capable of recognizing and interacting with a virus, and which, after binding it, are capable of generating some signal that initiates the chain of events leading to the biological response. Viral Entry Receptor,Viral Entry Receptors,Virus Attachment Factor,Virus Attachment Factors,Virus Attachment Receptor,Virus Attachment Receptors,Virus Entry Receptor,Virus Entry Receptors,Virus Receptor,Virus Receptors,Attachment Factor, Virus,Attachment Factors, Virus,Attachment Receptor, Virus,Attachment Receptors, Virus,Entry Receptor, Viral,Entry Receptor, Virus,Entry Receptors, Viral,Entry Receptors, Virus,Receptor, Viral Entry,Receptor, Virus,Receptor, Virus Attachment,Receptor, Virus Entry,Receptors, Viral Entry,Receptors, Virus Attachment,Receptors, Virus Entry
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004198 Disease Susceptibility A constitution or condition of the body which makes the tissues react in special ways to certain extrinsic stimuli and thus tends to make the individual more than usually susceptible to certain diseases. Diathesis,Susceptibility, Disease,Diatheses,Disease Susceptibilities,Susceptibilities, Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000349 Africa The continent south of EUROPE, east of the ATLANTIC OCEAN and west of the INDIAN OCEAN.
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte

Related Publications

M Seligmann, and A J Pinching, and F S Rosen, and J L Fahey, and R M Khaitov, and D Klatzmann, and S Koenig, and N Luo, and J Ngu, and G Riethmüller
January 1994, Advances in internal medicine,
M Seligmann, and A J Pinching, and F S Rosen, and J L Fahey, and R M Khaitov, and D Klatzmann, and S Koenig, and N Luo, and J Ngu, and G Riethmüller
April 1988, MMWR. Morbidity and mortality weekly report,
M Seligmann, and A J Pinching, and F S Rosen, and J L Fahey, and R M Khaitov, and D Klatzmann, and S Koenig, and N Luo, and J Ngu, and G Riethmüller
June 1989, MMWR. Morbidity and mortality weekly report,
M Seligmann, and A J Pinching, and F S Rosen, and J L Fahey, and R M Khaitov, and D Klatzmann, and S Koenig, and N Luo, and J Ngu, and G Riethmüller
January 1990, Disease markers,
M Seligmann, and A J Pinching, and F S Rosen, and J L Fahey, and R M Khaitov, and D Klatzmann, and S Koenig, and N Luo, and J Ngu, and G Riethmüller
June 1989, The American journal of medicine,
M Seligmann, and A J Pinching, and F S Rosen, and J L Fahey, and R M Khaitov, and D Klatzmann, and S Koenig, and N Luo, and J Ngu, and G Riethmüller
May 1992, Seminars in liver disease,
M Seligmann, and A J Pinching, and F S Rosen, and J L Fahey, and R M Khaitov, and D Klatzmann, and S Koenig, and N Luo, and J Ngu, and G Riethmüller
October 1997, Archives of dermatology,
M Seligmann, and A J Pinching, and F S Rosen, and J L Fahey, and R M Khaitov, and D Klatzmann, and S Koenig, and N Luo, and J Ngu, and G Riethmüller
January 1991, The Western journal of medicine,
M Seligmann, and A J Pinching, and F S Rosen, and J L Fahey, and R M Khaitov, and D Klatzmann, and S Koenig, and N Luo, and J Ngu, and G Riethmüller
March 1997, The Medical clinics of North America,
M Seligmann, and A J Pinching, and F S Rosen, and J L Fahey, and R M Khaitov, and D Klatzmann, and S Koenig, and N Luo, and J Ngu, and G Riethmüller
May 1990, The Tokai journal of experimental and clinical medicine,
Copied contents to your clipboard!